![](/img/cover-not-exists.png)
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E.Volume:
35
Language:
english
Journal:
Diabetes Care
DOI:
10.2337/dc11-1935
Date:
June, 2012
File:
PDF, 286 KB
english, 2012